Dicerna Aims to Gain Foothold in RNAi World With More Potent, Longer-Lasting Gene Silencers

Xconomy Boston — 

Most of the headlines in the RNA interference world go to Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY). While that company says it has amassed enough intellectual property—and cash—to dominate this emerging field of gene-silencing technologies for years, they aren’t the only game in town. One intriguing upstart of the RNAi field is a privately held company in Watertown, MA called Dicerna Pharmaceuticals.

Xconomy first covered the Dicerna story when it started in November 2007, and the company first hit my radar screen in July, when it raised $8.4 million to cap off a first-round financing of $21.4 million. It got the cash from Abingworth, Oxford Bioscience Partners, and Skyline Ventures. These people aren’t dabblers—Doug Fambrough of Oxford is a molecular biologist who invested in Sirna Therapeutics before that company was sold for $1.1 billion to Merck in 2006, and Steve Hoffman of Skyline was a fellow Sirna investor who also bet early on Alnylam. So I figured it was worth hearing more from Dicerna CEO Jim Jenson a couple weeks ago at the JP Morgan Healthcare Conference in San Francisco.

The idea behind RNAi-based drug development is to shut down disease at its roots, by using specially engineered RNA molecules to shut down production of specific disease-causing proteins. Dicerna was founded on the belief that there’s more than one way to achieve this; the company says it is working on a “second doorway” of RNA interference, by designing drugs that are a little longer than so-called small interfering RNA molecules being developed by Alnylam and others. The Dicerna method may have the added advantage of being more potent—meaning they can be given in lower doses, and could be cheaper to manufacture—and they may last longer in the body, meaning they could be given in fewer shots. Plus, they have a feature that will allow RNAi drugs to be bound together with other compounds like antibody fragments or peptides that could give them extra kick, say, against cancer cells.

All of this work is still being done in animals, so there’s no proof this works in people. But even with that limited evidence, and a grim investing climate, Jenson said he saw no shortage of interest among potential pharmaceutical partners at the JP Morgan meeting.

“It’s the real deal, the next game changer in drug development,” Jenson says. “Stay tuned, there is a very strong interest in our programs. Many people see the importance of this.”

Most small interfering RNA drugs tend to be 21 nucleotides, or chemical letters, long. The Dicerna drugs are a little longer, 27 nucleotides. This enables … Next Page »

Single PageCurrently on Page: 1 2

By posting a comment, you agree to our terms and conditions.

Comments are closed.